Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Dysfunctional striatal dopamine signaling in Huntington's disease.

Koch ET, Raymond LA.

J Neurosci Res. 2019 Dec;97(12):1636-1654. doi: 10.1002/jnr.24495. Epub 2019 Jul 15. Review.

PMID:
31304622
2.

Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease.

Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA.

Front Cell Neurosci. 2019 May 16;13:209. doi: 10.3389/fncel.2019.00209. eCollection 2019.

3.

Alterations in synaptic function and plasticity in Huntington disease.

Smith-Dijak AI, Sepers MD, Raymond LA.

J Neurochem. 2019 Aug;150(4):346-365. doi: 10.1111/jnc.14723. Epub 2019 Jun 6. Review.

PMID:
31095731
4.

Altered Regulation of Striatal Neuronal N-Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model.

Kang R, Wang L, Sanders SS, Zuo K, Hayden MR, Raymond LA.

Front Synaptic Neurosci. 2019 Feb 21;11:3. doi: 10.3389/fnsyn.2019.00003. eCollection 2019.

5.

Direct assessment of presynaptic modulation of cortico-striatal glutamate release in a Huntington's disease mouse model.

Koch ET, Woodard CL, Raymond LA.

J Neurophysiol. 2018 Dec 1;120(6):3077-3084. doi: 10.1152/jn.00638.2018. Epub 2018 Oct 17.

PMID:
30332323
6.

Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.

Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, Seth PP, Raymond LA, Frank Bennett C, Hayden MR.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaar3959. doi: 10.1126/scitranslmed.aar3959.

PMID:
30282695
7.

An Exploration of Parent-Youth Agreement on Functional Impairment in Adolescents Utilizing Outpatient Mental Health Services.

Yeh M, Zerr A, La R, McCabe K.

Healthcare (Basel). 2018 Aug 30;6(3). pii: E106. doi: 10.3390/healthcare6030106.

8.

Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.

Schmidt ME, Buren C, Mackay JP, Cheung D, Dal Cengio L, Raymond LA, Hayden MR.

BMC Biol. 2018 Jun 27;16(1):58. doi: 10.1186/s12915-018-0526-3.

9.

Cause or compensation?-Altered neuronal Ca2+ handling in Huntington's disease.

Mackay JP, Nassrallah WB, Raymond LA.

CNS Neurosci Ther. 2018 Apr;24(4):301-310. doi: 10.1111/cns.12817. Epub 2018 Feb 9. Review.

10.

Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.

Sepers MD, Smith-Dijak A, LeDue J, Kolodziejczyk K, Mackie K, Raymond LA.

J Neurosci. 2018 Jan 17;38(3):544-554. doi: 10.1523/JNEUROSCI.1739-17.2017. Epub 2017 Nov 30. Erratum in: J Neurosci. 2018 Aug 15;38(33):7364.

11.

An Automated Home-Cage System to Assess Learning and Performance of a Skilled Motor Task in a Mouse Model of Huntington's Disease.

Woodard CL, Bolaños F, Boyd JD, Silasi G, Murphy TH, Raymond LA.

eNeuro. 2017 Sep 18;4(5). pii: ENEURO.0141-17.2017. doi: 10.1523/ENEURO.0141-17.2017. eCollection 2017 Sep-Oct.

12.

Preliminary inter-rater reliability of the wheelchair components questionnaire for condition.

Rispin K, DiFrancesco J, Raymond LA, Riseling K, Wee J.

Disabil Rehabil Assist Technol. 2018 Aug;13(6):552-557. doi: 10.1080/17483107.2017.1346150. Epub 2017 Jul 7.

PMID:
28686490
13.

Characteristics and outcomes of Canadian MD/PhD program graduates: a cross-sectional survey.

Skinnider MA, Squair JW, Twa DDW, Ji JX, Kuzyk A, Wang X, Steadman PE, Zaslavsky K, Dey AK, Eisenberg MJ, Gagné ÈR, HayGlass KT, Lewis JF, Margetts PJ, Underhill DA, Rosenblum ND, Raymond LA.

CMAJ Open. 2017 Apr 25;5(2):E308-E314. doi: 10.9778/cmajo.20160152.

14.

Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death.

Divakaruni AS, Wallace M, Buren C, Martyniuk K, Andreyev AY, Li E, Fields JA, Cordes T, Reynolds IJ, Bloodgood BL, Raymond LA, Metallo CM, Murphy AN.

J Cell Biol. 2017 Apr 3;216(4):1091-1105. doi: 10.1083/jcb.201612067. Epub 2017 Mar 2.

15.

Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice.

Sanders SS, Parsons MP, Mui KK, Southwell AL, Franciosi S, Cheung D, Waltl S, Raymond LA, Hayden MR.

BMC Biol. 2016 Dec 7;14(1):108.

16.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

17.

Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response.

Graham HT, Rotroff DM, Marvel SW, Buse JB, Havener TM, Wilson AG, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators.

Front Genet. 2016 Aug 17;7:138. eCollection 2016.

18.

Striatal synaptic dysfunction and altered calcium regulation in Huntington disease.

Raymond LA.

Biochem Biophys Res Commun. 2017 Feb 19;483(4):1051-1062. doi: 10.1016/j.bbrc.2016.07.058. Epub 2016 Jul 14. Review.

PMID:
27423394
19.

An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.

Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, Xie Y, Anderson L, Felczak B, Waltl S, Ko S, Cheung D, Dal Cengio L, Slama R, Petoukhov E, Raymond LA, Hayden MR.

Hum Mol Genet. 2016 Sep 1;25(17):3654-3675. doi: 10.1093/hmg/ddw212. Epub 2016 Jul 4.

20.

Influence of cortical synaptic input on striatal neuronal dendritic arborization and sensitivity to excitotoxicity in corticostriatal coculture.

Buren C, Tu G, Parsons MP, Sepers MD, Raymond LA.

J Neurophysiol. 2016 Aug 1;116(2):380-90. doi: 10.1152/jn.00933.2015. Epub 2016 Apr 27.

21.

Real-time imaging of glutamate clearance reveals normal striatal uptake in Huntington disease mouse models.

Parsons MP, Vanni MP, Woodard CL, Kang R, Murphy TH, Raymond LA.

Nat Commun. 2016 Apr 7;7:11251. doi: 10.1038/ncomms11251.

22.

Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease.

Buren C, Parsons MP, Smith-Dijak A, Raymond LA.

Neurobiol Dis. 2016 Mar;87:80-90. doi: 10.1016/j.nbd.2015.12.009. Epub 2015 Dec 19.

PMID:
26711622
23.

Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.

Kolodziejczyk K, Raymond LA.

Neurobiol Dis. 2016 Feb;86:62-74. doi: 10.1016/j.nbd.2015.11.020. Epub 2015 Nov 24.

PMID:
26621114
24.

Motor onset and diagnosis in Huntington disease using the diagnostic confidence level.

Liu D, Long JD, Zhang Y, Raymond LA, Marder K, Rosser A, McCusker EA, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

J Neurol. 2015 Dec;262(12):2691-8. doi: 10.1007/s00415-015-7900-7. Epub 2015 Sep 26.

25.

Treatment of Huntington Disease and Comorbid Trichotillomania With Aripiprazole.

Howard AK, Krishnamoorthy A, Leavitt BR, Raymond LA, Weissman CR.

J Neuropsychiatry Clin Neurosci. 2015 Summer;27(3):e211-2. doi: 10.1176/appi.neuropsych.14090232. No abstract available.

PMID:
26222972
26.

Region-specific pro-survival signaling and global neuronal protection by wild-type Huntingtin.

Buren C, Wang L, Smith-Dijak A, Raymond LA.

J Huntingtons Dis. 2014;3(4):365-76. doi: 10.3233/JHD-140122.

PMID:
25575958
27.

LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.

Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, Chou P, Cao LP, Bergeron S, Mitchell E, Han H, Melrose HL, Tapia L, Raymond LA, Farrer MJ, Milnerwood AJ.

Hum Mol Genet. 2015 Mar 1;24(5):1336-49. doi: 10.1093/hmg/ddu543. Epub 2014 Oct 24.

PMID:
25343991
28.

Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.

Naydenov AV, Sepers MD, Swinney K, Raymond LA, Palmiter RD, Stella N.

Neurobiol Dis. 2014 Nov;71:140-50. doi: 10.1016/j.nbd.2014.08.009. Epub 2014 Aug 15.

29.

It's not necessarily all about the delivery in Huntington's disease.

Parsons MP, Raymond LA.

Neuron. 2014 Jul 2;83(1):6-8. doi: 10.1016/j.neuron.2014.06.009.

30.

Extrasynaptic NMDA receptor involvement in central nervous system disorders.

Parsons MP, Raymond LA.

Neuron. 2014 Apr 16;82(2):279-93. doi: 10.1016/j.neuron.2014.03.030. Review.

31.

Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease.

Kolodziejczyk K, Parsons MP, Southwell AL, Hayden MR, Raymond LA.

PLoS One. 2014 Apr 11;9(4):e94562. doi: 10.1371/journal.pone.0094562. eCollection 2014.

32.

Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease.

Sepers MD, Raymond LA.

Drug Discov Today. 2014 Jul;19(7):990-6. doi: 10.1016/j.drudis.2014.02.006. Epub 2014 Mar 3. Review.

PMID:
24603212
33.

Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.

Gladding CM, Fan J, Zhang LY, Wang L, Xu J, Li EH, Lombroso PJ, Raymond LA.

J Neurochem. 2014 Jul;130(1):145-59. doi: 10.1111/jnc.12700. Epub 2014 Apr 2.

34.

Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin.

Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN, Sanders SS, Hayden MR, Raymond LA.

J Biol Chem. 2014 Feb 7;289(6):3518-28. doi: 10.1074/jbc.M113.513945. Epub 2013 Dec 17.

35.

Memory and synaptic deficits in Hip14/DHHC17 knockout mice.

Milnerwood AJ, Parsons MP, Young FB, Singaraja RR, Franciosi S, Volta M, Bergeron S, Hayden MR, Raymond LA.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20296-301. doi: 10.1073/pnas.1222384110. Epub 2013 Nov 25.

36.

Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice.

Dau A, Gladding CM, Sepers MD, Raymond LA.

Neurobiol Dis. 2014 Feb;62:533-42. doi: 10.1016/j.nbd.2013.11.013. Epub 2013 Nov 19.

PMID:
24269729
37.

Refining the diagnosis of Huntington disease: the PREDICT-HD study.

Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group.

Front Aging Neurosci. 2013 Apr 2;5:12. doi: 10.3389/fnagi.2013.00012. eCollection 2013.

38.

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.

Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group.

Diabetes Care. 2013 Aug;36(8):2162-8. doi: 10.2337/dc12-1391. Epub 2013 Feb 14.

39.

Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.

Milnerwood AJ, Kaufman AM, Sepers MD, Gladding CM, Zhang L, Wang L, Fan J, Coquinco A, Qiao JY, Lee H, Wang YT, Cynader M, Raymond LA.

Neurobiol Dis. 2012 Oct;48(1):40-51. doi: 10.1016/j.nbd.2012.05.013. Epub 2012 Jun 2.

PMID:
22668780
40.

Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model.

Gladding CM, Sepers MD, Xu J, Zhang LY, Milnerwood AJ, Lombroso PJ, Raymond LA.

Hum Mol Genet. 2012 Sep 1;21(17):3739-52. doi: 10.1093/hmg/dds154. Epub 2012 Apr 20.

41.

Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons.

Kaufman AM, Milnerwood AJ, Sepers MD, Coquinco A, She K, Wang L, Lee H, Craig AM, Cynader M, Raymond LA.

J Neurosci. 2012 Mar 21;32(12):3992-4003. doi: 10.1523/JNEUROSCI.4129-11.2012.

42.

Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.

Park KH, Lu G, Fan J, Raymond LA, Leavitt BR.

J Huntingtons Dis. 2012;1(1):89-96. doi: 10.3233/JHD-2012-129000.

43.

P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.

Fan J, Gladding CM, Wang L, Zhang LY, Kaufman AM, Milnerwood AJ, Raymond LA.

Neurobiol Dis. 2012 Mar;45(3):999-1009. doi: 10.1016/j.nbd.2011.12.019. Epub 2011 Dec 14.

PMID:
22198502
44.

Synaptic dysfunction in progranulin-deficient mice.

Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, Gregg J, Lu G, Feldman HH, Mackenzie IR, Raymond LA, Leavitt BR.

Neurobiol Dis. 2012 Feb;45(2):711-22. doi: 10.1016/j.nbd.2011.10.016. Epub 2011 Oct 25.

PMID:
22062772
45.

Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS.

Neuroscience. 2011 Dec 15;198:252-73. doi: 10.1016/j.neuroscience.2011.08.052. Epub 2011 Aug 27. Review.

46.

Altered palmitoylation and neuropathological deficits in mice lacking HIP14.

Singaraja RR, Huang K, Sanders SS, Milnerwood AJ, Hines R, Lerch JP, Franciosi S, Drisdel RC, Vaid K, Young FB, Doty C, Wan J, Bissada N, Henkelman RM, Green WN, Davis NG, Raymond LA, Hayden MR.

Hum Mol Genet. 2011 Oct 15;20(20):3899-909. doi: 10.1093/hmg/ddr308. Epub 2011 Jul 20.

47.

Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function.

Gladding CM, Raymond LA.

Mol Cell Neurosci. 2011 Dec;48(4):308-20. doi: 10.1016/j.mcn.2011.05.001. Epub 2011 May 7. Review.

PMID:
21600287
48.

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT.

N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.

49.

NMDA Receptors and Huntington’s Disease.

Fernandes HB, Raymond LA.

In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 2.

50.

Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.

Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, Metzler M, Bissada N, Wang L, Faull RL, Gray M, Yang XW, Raymond LA, Hayden MR.

J Neurosci. 2010 Nov 10;30(45):15019-29. doi: 10.1523/JNEUROSCI.2071-10.2010.

Supplemental Content

Loading ...
Support Center